Your browser doesn't support javascript.
loading
A case of azathioprine-induced aplastic anemia.
Montgomery, Hunter D; Agarwal, Archana M; Lim, Ming Y.
Affiliation
  • Montgomery HD; School of Medicine, University of Utah, Salt Lake City, Utah, USA.
  • Agarwal AM; Department of Pathology, University of Utah, Salt Lake City, Utah, USA.
  • Lim MY; Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
Int J Lab Hematol ; 44(6): 1015-1016, 2022 Dec.
Article in En | MEDLINE | ID: mdl-35799500
ABSTRACT
Azathioprine (AZA) is an immunosuppressant that is widely used to treat many disease states including rheumatoid arthritis. We present a patient who was treated with AZA for rheumatoid arthritis and subsequently hospitalized for severe myelosuppression due to acquired aplastic anemia. Upon genetic testing it was found that the patient was thiopurine methyltransferase (TMPT) deficient, a well-documented risk factor for myelosuppression in patients taking azathioprine. We advocate for TPMT and nudix hydrolase 15 (NUDT15) testing prior to initiation of AZA treatment, or close monitoring with a complete blood count post-AZA initiation to avoid these serious side effects.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Anemia, Aplastic Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Int J Lab Hematol Journal subject: HEMATOLOGIA Year: 2022 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Anemia, Aplastic Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Int J Lab Hematol Journal subject: HEMATOLOGIA Year: 2022 Document type: Article Affiliation country: